GlaxoSmithKline

GlaxoSmithKline plc (NYSE:GSK)'s price-to-sales ratio of 2.34 is creating a long-term opportunity in the value in its stock. The broad GlaxoSmithKline plc industry has an average P/S ratio of 4.78, which is significantly better than the sector's 7.6. In the past 13-year record, this ratio went down as low as 1.94 ...

GlaxoSmithKline (LON:GSK)'s stock had its “hold” rating reiterated by investment analysts at Deutsche Bank in a report issued on Friday, March 23rd, MarketBeat.com reports. They presently have a GBX 1,440 ($20.62) target price on the stock. Deutsche Bank's price target would suggest a potential upside ...

The US broker Jefferies has tweaked its price targets for AstraZeneca PLC (LON:AZN) and GlaxoSmithKline PLC (LON:GSK) ahead of first-quarter results, while maintaining its positive stance on the stocks of both businesses. AZ's valuation moves to £56 a share, around £6 higher than the current share ...

GlaxoSmithKline plc (LSE:GSK) is considered a high growth stock. However its last closing price of £14.296 left investors wondering whether this growth has already been factored into the share price. Below I will be talking through a basic metric which will help answer this question. Check out our latest ...

PetMed Express (NASDAQ:PETS): Cramer likes the stock but he prefers Idexx Labs (NASDAQ:IDXX) and Zoetis (NYSE:ZTS) more. Novartis AG (NYSE:NVS): It's a good stock. However, Cramer prefers GlaxoSmithKline (NYSE:GSK) as the stock yields 6% and CEO Emma Walmsley is turning the industry ...

British pharmaceutical major GlaxoSmithKline is putting Horlicks up for sale. The health food drink brand sold widely in India and also consumed in parts of Asia and the UK is up for a “strategic review,” the company said in a statement on March 27. The move is triggered by GSK's need to fund a $13 billion ...

The British pharma giant GlaxoSmithKline has had a consumer health joint venture with Switzerland's Novartis for the last few years. However, GSK has just struck a $13 billion deal with its partner to take control of the whole thing. The joint venture sells products such as Nicotinell nicotine patches, Panadol ...

GlaxoSmithKline logo GlaxoSmithKline (NYSE:GSK) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, February 21st. According to Zacks, “Glaxo beat estimates for both earnings and sales in Q4. Performance of new products has been ...

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Once again, our agenda is modest. We hope to catch up on our reading, escort Mrs. Pharmalot to a highbrow cultural establishment and take ...

If we could take a snapshot right now, there would be three major arguments for buying GlaxoSmithKline stock. First, the company's dividend yields 6.88%. That's the highest yield among big pharma companies and one of the highest yields in healthcare. Although Glaxo hasn't increased its dividend in a ...

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by ...

As a severe flu season continues to unfold in the U.S., GlaxoSmithKline is touting phase 3 study data showing its Fluarix Tetra can protect young children who ... In children six to 35 months of age, Glaxo's vaccine was 63.2% effective against moderate-to-severe flu, and 49.8% effective against any flu, the ...

GlaxoSmithKline logo Brandes Investment Partners LP lifted its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 6.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,262,946 shares of the pharmaceutical company's ...

GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals Intl (NYSE:VRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ...

2/27/2018 – GlaxoSmithKline had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a GBX 1,925 ($26.60) price target on the stock. 2/26/2018 – GlaxoSmithKline was given a new GBX 1,475 ($20.38) price target on by analysts at Jefferies Group LLC. They now have a “buy” rating ...

GlaxoSmithKline has seen precious few takers for its $730,000 gene therapy for a rare and life-threatening immune illness known as “bubble-boy disease.” Now a tiny startup thinks it can succeed where the British giant is struggling. In almost two years since Glaxo's Strimvelis came to the market, just five ...

“This study is a valuable addition to our understanding of how to manage patients with biologic therapies,” study investigator Ken Champan said in a statement. Glaxo, though, has more to worry about in terms of competition than just Xolair. While Teva's Cinqair has been in the mix since March, 2016, the ...

GlaxoSmithKline PLC (GSK.LN) said on Monday that its majority-owned ViiV Healthcare joint venture has reported positive interim results from a study of dolutegravir, a treatment for adults with both HIV and tuberculosis. GSK said the ViiV phase IIIb study of dolutegravir showed the treatment was effective ...

GlaxoSmithKline plc (NYSE:GSK) delivered an ROE of 62.17% over the past 12 months, which is an impressive feat relative to its industry average of 10.75% during the same period. However, whether this above-industry ROE is actually impressive depends on if it can be maintained. Sustainability can be ...

For example, analysts who follow Glaxo have been raising their earnings projections going forward and with good reason. Bears zone in too much on future Advair competition (which has been kept at bay for the most part) but ignore what Glaxo has coming down the track. Furthermore the viability of the ...

Endo, GlaxoSmithKline close to settling testosterone liability cases ... Endo and GlaxoSmithKline have entered into a memorandum of understanding regarding a potential testosterone settlement. (Image: Pixabay) ... They're joined as defendants in some cases by former marketing partner GlaxoSmithKline.

GlaxoSmithKline said it will also receive a seat on the board of the gene-therapy company. The deal comes after a review by the British pharmaceutical major of its rare-disease unit. Glaxo cited as part of the rationale for the deal its decision to focus on respiratory and HIV/infectious-disease programs as ...

GlaxoSmithKline (GSK) is a British multinational pharmaceutical company with headquarters in Brentford, Middlesex. The company classifies its business portfolio into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Because it's a British multinational company, GSK ...

With analysts forecasting GlaxoSmithKline plc (LSE:GSK) to report triple digit earnings growth in the coming 12 months, it's important to take a step back and think through this promising sentiment. Those invested in the stock should contemplate the factors that are causing this projected increase, as the ...